BioCatalyst

IBRX — ImmunityBio, Inc. catalysts

2 verified catalyst event(s) for ImmunityBio, Inc. (ticker IBRX). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-07-01 — A Study to Examine Anktiva for the Treatment of COVID-19. · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-07 (month)
in 9d
ESTIMATED
 READOUT
A Study to Examine Anktiva for the Treatment of COVID-19.
Phase 2 · Long COVID, Long COVID Syndrome
 IBRX ImmunityBio, Inc. Anktiva ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-10 (month)
in 3mo
ESTIMATED
 READOUT
A Study to Assess Anktiva in Patients With Long Covid-19.
Phase 2 · Long COVID
 IBRX ImmunityBio, Inc. N-803 (IL-15 Superagonist) ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.